InsiderTrades.com logo

Scott Gangloff Biography and Net Worth

CTO of Akero Therapeutics
  • LinkedIn
  • Phone
  • Email
  • Website


Scott Gangloff is chief technical officer of Akero. He brings 28 years of experience in biopharmaceutical development and manufacturing and has led these aspects for numerous products, leading to several biologics approvals in the US, Europe, and other global markets for oncology and immunology programs. Scott joined Akero from Incyte Corporation, where he served as vice president, global biopharmaceutical development, responsible for CMC development and supply-chain activities for the large molecule pipeline. Scott also has built bioprocess, pharmaceutical development, and manufacturing teams in both the start-up and large pharma environments at Oncobiologics and Bristol-Myers Squibb. Scott holds a master of engineering in chemical engineering from Lehigh University.

What is Scott A. Gangloff's net worth?

The estimated net worth of Scott A. Gangloff is at least $1.28 million as of June 18th, 2025. Mr. Gangloff owns 23,452 shares of Akero Therapeutics stock worth more than $1,281,183 as of December 4th. This net worth approximation does not reflect any other assets that Mr. Gangloff may own. Learn More about Scott A. Gangloff's net worth.

How old is Scott A. Gangloff?

Mr. Gangloff is currently 50 years old. There are 7 older executives and no younger executives at Akero Therapeutics. The oldest executive at Akero Therapeutics is Dr. Timothy Rolph, Co-Founder & Chief Scientific Officer, who is 70 years old. Learn More on Scott A. Gangloff's age.

How do I contact Scott A. Gangloff?

The corporate mailing address for Mr. Gangloff and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at [email protected]. Learn More on Scott A. Gangloff's contact information.

Has Scott A. Gangloff been buying or selling shares of Akero Therapeutics?

Scott A. Gangloff has not been actively trading shares of Akero Therapeutics during the last ninety days. Most recently, Scott A. Gangloff sold 848 shares of the business's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $54.84, for a transaction totalling $46,504.32. Following the completion of the sale, the chief technology officer now directly owns 23,452 shares of the company's stock, valued at $1,286,107.68. Learn More on Scott A. Gangloff's trading history.

Who are Akero Therapeutics' active insiders?

Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), Scott Gangloff (CTO), Tomas Heyman (Director), Patrick Lamy (SVP of Commercial Strategy ), Timothy Rolph (Co-Founder and Chief Scientific Officer), Graham Walmsley (Director), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.

Are insiders buying or selling shares of Akero Therapeutics?

During the last twelve months, Akero Therapeutics insiders bought shares 3 times. They purchased a total of 341,309 shares worth more than $15,863,577.75. During the last twelve months, insiders at the sold shares 69 times. They sold a total of 737,859 shares worth more than $35,038,065.72. The most recent insider tranaction occured on October, 10th when CEO Andrew Cheng sold 30,000 shares worth more than $1,619,400.00. Insiders at Akero Therapeutics own 7.1% of the company. Learn More about insider trades at Akero Therapeutics.

Information on this page was last updated on 10/10/2025.

Scott A. Gangloff Insider Trading History at Akero Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/18/2025Sell848$54.84$46,504.3223,452View SEC Filing Icon  
See Full Table

Scott A. Gangloff Buying and Selling Activity at Akero Therapeutics

This chart shows Scott A Gangloff's buying and selling at Akero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Akero Therapeutics Company Overview

Akero Therapeutics logo
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $54.63
Low: $54.53
High: $54.69

50 Day Range

MA: $52.78
Low: $46.00
High: $54.69

2 Week Range

Now: $54.63
Low: $21.34
High: $58.40

Volume

2,283,430 shs

Average Volume

1,484,302 shs

Market Capitalization

$4.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A